Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

141. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143) Adalimumab, etanercept and infliximab for ankylosing spondylitis | Guidance | NICE Adalimumab, etanercept and infliximab for ankylosing spondylitis Technology appraisal guidance [TA143] Published date: 28 May 2008 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

142. Adalimumab for the treatment of adults with psoriasis (TA146)

Adalimumab for the treatment of adults with psoriasis (TA146) Overview | Adalimumab for the treatment of adults with psoriasis | Guidance | NICE Adalimumab for the treatment of adults with psoriasis Technology appraisal guidance [TA146] Published date: 25 June 2008 Share Guidance on adalimumab (Humira) for treating psoriasis in adults. Since this guidance was published, an equality consideration has been raised about the PASI instrument. When using the Psoriasis Area Severity Index (PASI (...) ), healthcare professionals should take into account skin colour and how this could affect the PASI score, and make the clinical adjustments they consider appropriate. The recommendations also apply to adalimumab biosimilar products that have a marketing authorisation allowing the use of the biosimilar for the same indication. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

143. Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please

2007 NIHR HTA programme

144. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technology Assessment 2007; 11(28): 1-158 Authors' objectives "The objectives of this review were to assess the comparative clinical effectiveness

2007 Health Technology Assessment (HTA) Database.

145. Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing

Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing National Horizon Scanning Centre Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation National Horizon Scanning Centre. Adalimumab (Humira) for juvenile idiopathic arthritis: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2007 Authors' objectives This study examines the use of Adalimumab (Humira) for juvenile idiopathic arthritis. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Arthritis, Juvenile Rheumatoid /drug therapy Language Published English Country of organisation England Address

2007 Health Technology Assessment (HTA) Database.

146. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness

Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis (...) and review of comparative clinical- and cost-effectiveness Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis

2007 Health Technology Assessment (HTA) Database.

147. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis (Full text)

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Walsh C A, Minnock P, Slattery C, Kennedy N, Pang F, Veale D J, Bresnihan B, FitzGerald (...) ' therapy) to adalimumab. The mean infliximab dosage was 5 mg/kg every 8 weeks. When patients were switched to adalimumab they received 40 mg subcutaneously every other week. One-year extrapolation data were also presented. Type of intervention Treatment. Economic study type Cost-effectiveness analysis Study population Eligible individuals were those with RA and responders to at least 12 weeks' infliximab, but with ongoing, varying levels of disease activity. They had to be willing to self-administer

2007 NHS Economic Evaluation Database. PubMed

148. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis (Full text)

Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Kaplan G G, Hur C, Korzenik J, Sands B E Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to determine if dose escalation of infliximab was cost-effective in comparison with adalimumab initiation after loss of response to infliximab in patients with Crohn’s disease. The authors concluded that dose escalation would yield more quality

2007 NHS Economic Evaluation Database. PubMed

149. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill R A, Jones A, Mujica Mota R, Walley T CRD summary (...) This review, which assessed the clinical effectiveness of anti-tumour necrosis factor-α therapy for patients with ankylosing spondylitis, concluded that the therapy is clinically effective in the short term. The authors' conclusions are likely to be reliable. Authors' objectives To assess the comparative clinical effectiveness and cost-effectiveness of anti-tumour necrosis factor (TNF)-α therapy (adalimumab, etanercept and infliximab) for the treatment of ankylosing spondylitis. This abstract will only

2007 DARE.

150. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response (...) in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T CRD summary This review compared tumour necrosis factor-alpha blocking drugs for rheumatoid arthritis and concluded that adalimumab, etanercept and infliximab had similar efficacy, but infliximab may need higher doses for a similar effect. Given that this was based on an indirect comparison of only one trial of each

2007 DARE.

151. Adalimumab - Arthritis, rheumatoid

Adalimumab - Arthritis, rheumatoid CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB (Humira™--Abbott Laboratories, Limited) Description: Adalimumab is indicated for reducing the signs and symptoms, and inhibiting the progression of structural damage, in adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be used alone or in combination (...) with methotrexate or other DMARDs. Recommendation: CEDAC recommends that adalimumab be listed for patients with moderate to severe active RA who meet current drug plan criteria for funding of infliximab or etanercept (i.e. patients must be refractory to or intolerant of at least two potent DMARDs, including methotrexate and leflunomide). The number of doses should be limited to twenty-six 40 mg doses per year with no dose escalation permitted. Adalimumab should not be used in combination with other tumor

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

152. Adalimumab - Arthritis, psoriatic

Adalimumab - Arthritis, psoriatic Common Drug Review CEDAC Meeting – October 18; 2006 Page 1 of 3 Notice of CEDAC Final Recommendation – November 29, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB RESUBMISSION (Humira ® - Abbott Laboratories Ltd.) Description: Adalimumab is a human monoclonal antibody to tumour necrosis factor (TNF). The Canadian Expert Drug Advisory Committee had previously recommended that adalimumab be listed for patients with moderate to severe (...) active rheumatoid arthritis who meet current drug plan criteria for funding of infliximab or etanercept (see Notice of CEDAC Final Recommendation on adalimumab issued on February 11, 2005). A new indication for use in psoriatic arthritis was the basis for the resubmission. Adalimumab is approved for reducing the signs and symptoms of active arthritis in adult psoriatic arthritis patients. Dosage Forms: 40 mg in 0.8 mL solution for subcutaneous injection. The recommended dose is 40 mg every two weeks

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

153. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

154. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis | Guidance | NICE Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis Technology appraisal guidance [TA130] Published date: 22 October 2007 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2007 National Institute for Health and Clinical Excellence - Technology Appraisals

155. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display

2006 NIHR HTA programme

156. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) arthritis in adults and an economic evaluation of their cost-effectiveness Chen Y F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A CRD summary This review concluded that adalimumab, etanercept and infliximab are effective treatments compared with placebo for patients with rheumatoid arthritis who are not well-controlled by disease-modifying antirheumatic drugs. Combination with methotrexate seems more effective in early rheumatoid arthritis. An increased risk of infection may

2006 DARE.

157. Use of adalimumab (Humira®) within NHS Wales

Use of adalimumab (Humira®) within NHS Wales Use of adalimumab (Humira®) within NHS Wales Use of adalimumab (Humira®) within NHS Wales All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Use of adalimumab (Humira®) within NHS Wales. Penarth: All Wales Therapeutics and Toxicology

2006 Health Technology Assessment (HTA) Database.

158. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis

Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No.79. 2006 Authors' objectives The aim of this report was to assess the use of etanercept, infliximab and adalimumab

2006 Health Technology Assessment (HTA) Database.

159. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) arthritis in adults and an economic evaluation of their cost-effectiveness Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab

2006 Health Technology Assessment (HTA) Database.

160. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn`s disease: the CLASSIC-I trial. (PubMed)

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn`s disease: the CLASSIC-I trial. BACKGROUND & AIMS: Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn's disease (CD). Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor (TNF). A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients (...) with CD. METHODS: A total of 299 patients with moderate to severe CD naive to anti-TNF therapy were randomized to receive subcutaneous injections at weeks 0 and 2 with adalimumab 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg or placebo. The primary endpoint was demonstration of a significant difference in the rates of remission at week 4 (defined as a Crohn's Disease Activity Index score <150 points) among the 80 mg/40 mg, 160 mg/80 mg, and placebo groups. RESULTS: The rates of remission at week 4

2006 EvidenceUpdates